Summary and Conclusions

SBU's appraisal of the evidence
During birth, asphyxia occurs when the child suffers a combination of oxygen deficiency and reduced blood supply. In serious cases of asphyxia, the infant can develop symptoms of brain damage shortly following birth, ie, hypoxic ischemic encephalopathy (HIE). In moderate to severe asphyxia the lack of oxygen can cause serious damage to the brain and other organs, and some of the infants die. Children who survive are at higher risk for moderate or severe functional im pairments, eg, cerebral palsy (CP) or impaired vision and hear ing. Therapeutic hypothermia is a new method for treating HIE following birth asphyxia and is used to complement standard treatment.
• In full-term newborns affected by moderate or severe symptoms of brain injury (HIE) due to severe birth asphyxia, therapeutic hypothermia reduces the risk of death or severe functional impairment in the child (Evidence Grade 2)*. However, the scientific evi dence is insufficient* to appraise the method's effect beyond 18 months.
• The scientific evidence is insufficient* to draw firm con clusions on the adverse effects and complications related to therapeutic hypothermia. No serious adverse effects or complications have been identified in the studies reviewed for this report, but the studies were not specifically designed to investigate this.
• The scientific evidence is insufficient* to draw firm conclusions on the cost-effectiveness of the method. However, the fact that the extra costs for this method are relatively moderate and the outcomes are good would suggest that the method is cost-effective.
• The optimum way (best practice) to deliver treatment is not clear. Hence, it is important to monitor the experi ences and outcomes of treatment, eg, via a central quality register. Also, continued research is essential to gain knowledge about best practices as well as the potential complications and adverse effects. patient benefit Three systematic reviews, ap praised to be of high quality, show that therapeutic hypothermia of full-term infants with moderate or severe HIE following severe birth asphyxia reduces the risk of death or survival with severe functional disabilities. The children were followed until they were at least 12 SBU Alert is a service provided by SBU in collaboration with the Medical Products Agency, the National Board of Health and Welfare, and the Swedish Association of Local Authorities and Regions Therapeutic Hypothermia Following Perinatal Asphyxia sbu alert - early assessment of new health technologies • www.sbu.se/alert months of age, but no older than 18 months. The results are statistically significant and clinically meaningful. The relative risk reduction was 22% to 24%, and the absolute risk reduction was 14 to 16 percentage points. This means that of 100 children with HIE who receive therapeutic hypo thermia, on average 14 to 16 more children will survive without severe functional disabilities compared to if they hadn't received therapeutic hypothermia. In sep arate analyses of the two endpoints, ie, death and survival with moderate/severe functional disabilities, the reviews show that therapeutic hypothermia reduces risk for both outcomes.
No serious adverse effects or complications related to therapeutic hypothermia have been identified in the studies reviewed in this report, but there are no wellexecuted studies that have been specifically designed to investigate this.
ethical aspects The quality of life for children receiving therapeutic hypothermia increases since fewer children die and fewer have severe functional disabilities. Likewise, the quality of life for parents and siblings also increases. This, however, must be weighed against the uncertainty regarding the optimum way to deliver the treatment and its long-term effects.
Therapeutic hypothermia must begin within 6 hours of birth. Access to therapeutic hypothermia varies in differ ent parts of Sweden. Hence, there is a risk that therapeutic hypothermia cannot be offered within 6 hours to all children needing this care, which conflicts with the so-called equity principle in Sweden. Given the current diffusion of this method, hospitals need to have a high level of collaboration and a well functioning transportation system.
Starting therapeutic hypothermia requires an immediate decision. Hence, healthcare staff do not always have time to confer with the child's parents before starting treatment. As quickly as possible, the parents should receive comprehensive, objective, and well-designed information about the method's potential benefits and risks.
When the method is introduced in clinical practice there is a risk that the inclusion criteria used in the research studies, and which are currently recommended for clinic al use, will not be strictly applied. This could result in treating children who are too severely damaged to benefit from therapeutic hypothermia, leading to survival with very severe functional disabilities that affect quality of life not only for the child, but also for the family. Less strin gent application could also lead to unnecessarily treat ing children who do not have sufficiently severe injuries, and hence do not meet the criteria for therapeutic hypothermia. Against this background, it is important to follow the children who are treated and to coordinate this data in a quality register. Assuming that all children who require therapeutic hypothermia can receive it, that the parents' informational needs are met, and that the children are carefully followed up, the method is ap praised to be ethically defensible given its benefits regarding qual ity of life. economic aspects The average extra cost per child receiving therapeutic hypothermia is roughly estimated at 5000 to 10 000 Swedish kronor (SEK), including the extra staff costs during the care episode. Additional costs would include any costs for transportation to and from the home hospital and the cost for followup examinations of the child's motor and cognitive development. The only health economic study available, an American model study, shows that therapeutic hypothermia offers better effects at a lower cost than does the option of not using therapeutic hypothermia.
Criteria for Evidence Grading SBU's Conclusions
Evidence Grade 1 -Strong Scientific Evidence. The conclusion is corroborated by at least two independent studies with high quality, or a good systematic overview. Evidence Grade 2 -Moderately Strong Scientific Evidence. The conclusion is corroborated by one study with high quality, and at least two studies with medium quality. Evidence Grade 3 -Limited Scientific Evidence. The conclusion is corroborated by at least two studies with medium quality. Insufficient Scientific Evidence -No conclusions can be drawn when there are not any studies that meet the criteria for quality. Contradictory Scientific Evidence -No conclusions can be drawn when there are studies with the same quality whose findings contradict each other.
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